SCHEMBL4817364

SCHEMBL4817364

Fc1cccc(F)c1-c1c(Cl)nc2ncnn2c1N1CC=CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.38
NPSR1 Q6W5P4 3/20 0.38
GLA P06280 1/20 0.38
SMN1; SMN2 Q16637 5/20 0.35
KMT2A Q03164 4/20 0.35
MEN1 O00255 3/20 0.35
MAPT P10636 2/20 0.35
HTT P42858 2/20 0.35
ALDH1A1 P00352 8/20 0.35
POLB P06746 1/20 0.35
LMNA P02545 3/20 0.34
APP P05067 1/20 0.34
HPGD P15428 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
USP2 O75604 1/20 0.33
TP53 P04637 1/20 0.33
ALOX15 P16050 1/20 0.33
MAPK1 P28482 1/20 0.33
HSD17B10 Q99714 1/20 0.33
PDE2A O00408 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4821688 0.92 TSHR (0.37) TSHRNPSR1GLASMN1; SMN2KMT2A
SCHEMBL8916786 0.89 TSHR (0.40) TSHRNPSR1GLASMN1; SMN2KMT2A
SCHEMBL4821987 0.89 TSHR (0.40) TSHRNPSR1GLASMN1; SMN2KMT2A
SCHEMBL8912337 0.86 TSHR (0.36) TSHRNPSR1GLASMN1; SMN2KMT2A
SCHEMBL4821049 0.85 TSHR (0.42) TSHRNPSR1GLASMN1; SMN2KMT2A
SCHEMBL4820371 0.84 TSHR (0.48) TSHRNPSR1GLASMN1; SMN2KMT2A
SCHEMBL4817651 0.84 TSHR (0.41) TSHRNPSR1GLASMN1; SMN2KMT2A
SCHEMBL4818210 0.84 TSHR (0.41) TSHRNPSR1GLASMN1; SMN2KMT2A
SCHEMBL8916197 0.83 PDE2A (0.39) TSHRNPSR1GLASMN1; SMN2KMT2A
SCHEMBL4820465 0.83 PDE2A (0.39) TSHRNPSR1GLASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020068744-A1 Substituted-triazolopyrimidines as anticancer agents AMERICAN HOME PRODUCTS CORPORATION 2002-06-06 US claimed
US-7329663-B2 Substituted-triazolopyrimidines as anticancer agents WYETH (US) 2008-02-12 US disclosed
US-20020068744-A1 Substituted-triazolopyrimidines as anticancer agents AMERICAN HOME PRODUCTS CORPORATION 2002-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068744-A1 Substituted-triazolopyrimidines as anticancer agents TUBB3, TUBA1C, TUBB1 TSHR 2567/4885NPSR1 4247/4885GLA 3009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.